Empirical Asset Management LLC Invests $1.09 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Empirical Asset Management LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 22,810 shares of the biopharmaceutical company's stock, valued at approximately $1,091,000.

Other hedge funds have also added to or reduced their stakes in the company. Envestnet Asset Management Inc. boosted its stake in shares of Halozyme Therapeutics by 4.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 229,620 shares of the biopharmaceutical company's stock valued at $12,023,000 after purchasing an additional 10,651 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Halozyme Therapeutics by 12.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company's stock valued at $99,363,000 after acquiring an additional 209,530 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $182,000. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Halozyme Therapeutics by 13.5% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 20,711 shares of the biopharmaceutical company's stock worth $1,084,000 after acquiring an additional 2,463 shares during the period. Finally, Intech Investment Management LLC bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $1,192,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HALO shares. HC Wainwright lifted their price target on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a "buy" rating in a research report on Friday, January 10th. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Wells Fargo & Company decreased their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. JMP Securities upped their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a report on Friday, November 1st. Finally, Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $60.89.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the business's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares of the company's stock, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.70% of the company's stock.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO traded down $0.57 during mid-day trading on Friday, hitting $54.80. 942,028 shares of the company traded hands, compared to its average volume of 1,331,984. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The stock's fifty day moving average price is $49.62 and its 200-day moving average price is $54.12. The firm has a market cap of $6.97 billion, a price-to-earnings ratio of 18.15, a price-to-earnings-growth ratio of 0.40 and a beta of 1.24. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.